EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries
| Revenue (Most Recent Fiscal Year) | $862.40M |
| Net Income (Most Recent Fiscal Year) | $-212.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.40 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -25.08% |
| Net Margin (Trailing 12 Months) | -26.34% |
| Return on Equity (Trailing 12 Months) | -21.51% |
| Return on Assets (Trailing 12 Months) | -10.54% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.46 |
| Inventory Turnover (Trailing 12 Months) | 19.69 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 355.11M |
| Free Float | 351.56M |
| Market Capitalization | $1.34B |
| Average Volume (Last 20 Days) | 0.18M |
| Beta (Past 60 Months) | 1.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 5.81% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |